Holen Sie sich die Stockscreener-App
22.51
3.02%
-0.70
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Can Ultragenyx Pharmaceutical Inc. stock rebound after recent weaknessMarket Movers & Fast Momentum Entry Tips - ulpravda.ru
Why Ultragenyx Pharmaceutical Inc. stock is trending among retail tradersPrice Action & Low Risk Entry Point Guides - ulpravda.ru
Analysts Lower Ultragenyx (RARE) Target but Stay Bullish - Insider Monkey
Looking Into Ultragenyx Pharmaceutical Inc's Recent Short Interest - Sahm
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
RARE ALERT: Ongoing Investigation Into Ultragenyx Pharmaceutical Inc.Contact Levi & Korsinsky - ACCESS Newswire
Ongoing Investigation into Ultragenyx Pharmaceutical Inc. (RARE): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
How Ultragenyx Pharmaceutical Inc. stock valuations compare to rivals2025 Volatility Report & Safe Entry Trade Reports - ulpravda.ru
2026-01-08 | Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:RARE | Press Release - Stockhouse
Is Ultragenyx Pharmaceutical Inc. (UP0) stock a buy before earnings results2025 Dividend Review & AI Based Trade Execution Alerts - ulpravda.ru
Looking at the Latest Short Interest Activity for Ultragenyx Pharmaceutical Inc - Bitget
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
RBC Cuts Price Target on Ultragenyx Pharmaceutical to $35 From $72, Keeps Outperform, Speculative Risk - MarketScreener
Kyowa Kirin and Ultragenyx to proceed with US regulatory bid for burosumab - The Pharma Letter
Ultragenyx Pharmaceutical Inc. CEO to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Does Ultragenyx Pharmaceutical Inc. (UP0) stock trade below intrinsic valueCandlestick Trading Patterns & Affordable Trading Growth - ulpravda.ru
2026-01-07 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Connect | NDAQ:RARE | Press Release - Stockhouse
What is HC Wainwright's Estimate for RARE FY2025 Earnings? - MarketBeat
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire
MarketsMedicine Hat News - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx ... - Bluefield Daily Telegraph
Ultragenyx Pharma stock price target lowered to $60 at H.C. Wainwright - Investing.com Nigeria
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A 197% Upside Potential that Grabs Investor Attention - DirectorsTalk Interviews
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
ATTENTION Ultragenyx Pharmaceutical Inc. (RARE) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound - MSN
Ultragenyx Finishes Rolling Submission of BLA for Glycogen Storage Disease Gene Therapy DTX401 - CGTLive®
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Ultragenyx Pharmaceutical (RARE) Target Price Lowered by HC Wain - GuruFocus
HC Wainwright Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $60.00 - MarketBeat
Guggenheim lowers Ultragenyx Pharma stock price target on trial failures By Investing.com - Investing.com Nigeria
2026-01-05 | Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:RARE | Press Release - Stockhouse
Ultragenyx Pharmaceutical (RARE): Guggenheim Lowers Price Target - GuruFocus
Guggenheim lowers Ultragenyx Pharma stock price target on trial failures - Investing.com
Guggenheim Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical (RARE) Advances Gene Therapies, But How Durable Is Its Rare-Disease Strategy? - Yahoo Finance
Ultragenyx Pharmaceutical (RARE) Is Down 31.0% After Rare-Disease Milestone UpdatesHas The Bull Case Changed? - Sahm
Ultragenyx completes rolling FDA submission for US approval of gene therapy - MSN
StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures - Genetic Engineering and Biotechnology News
ATTENTION RARE Shareholders: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide - Benzinga
Ultragenyx stock eyes best day in 17 months as Wall Street shifts focus to 2026 pipeline after bone disease trial miss - MSN
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
Levi & Korsinsky Investigates Possible Securities Fraud by Ultragenyx Pharmaceutical Inc. (RARE) - ACCESS Newswire
Ultragenyx Phase III Data Reveal Limits of Bone Density Endpoints in Rare Bone Disease - BioPharm International
Bank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Pharmaceutical (RARE): B of A Securities Lowers Price Target | RARE Stock News - GuruFocus
Ultragenyx completes rolling submission of BLA for DTX401 - The Pharma Letter
Ultragenyx Pharmaceuticals Loses $1 Billion in Market Value After Bone Drug Fails Phase III Trials - geneonline.com
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials By Investing.com - Investing.com South Africa
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures - BioSpace
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):